The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix

The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix.
Higher doses of the blood-thinner Plavix were no better at preventing nitty-gritty attacks, blood clots or undoing than the archetype crop quantity in patients who had received artery-opening stents, new inquire into shows. The higher dose - false the usual amount - was tested in patients with "high platelet reactivity," sense they failed to respond to the drug at lower doses virilityex.herbalous.com. Plavix (clopidogrel) helps thwart clots from forming in patients who have glum platelet reactivity and who have had stents inserted to prop ice-free blocked arteries.

But the new study "doesn't support" physicians using the higher, 150-milligram administer of Plavix after stenting, according to analyse lead author Dr Matthew Price, who presented the findings Tuesday at the annual congress of the American Heart Association in Chicago. So, the inquiry leaves an important question unanswered: How to prescribe for heart patients who don't respond well to Plavix? "It remains vague to some extent," said Dr Abhiram Prasad, an interventional cardiologist with the Mayo Clinic in Rochester, Minn supplements. "It's an superior research to have done but the key issues are that a significant ration of the patients remained with high platelet reactivity even after being on the higher dose".

Previous, smaller studies had indicated that Plavix might have more of an accomplish if the measure was doubled. "Platelet reactivity varies widely," noted Price, captain of the Cardiac Catheterization Laboratory at the Scripps Clinic in La Jolla, Calif. He explained that numerous studies have shown that a exalted reactivity stage is associated with poorer outcomes after angioplasty and/or stenting. But until now, a abrupt rise in the dosage of Plavix "has not been tested in a large randomized clinical trial".